Factors impacting the combination of topical corticosteroid therapies for psoriasis: perspectives from the international psoriasis council
SourceJEADV : Journal of the European Academy of Dermatology and Venereology, 25, 10, (2011), pp. 1130-9
Article / Letter to editor
Display more detailsDisplay less details
JEADV : Journal of the European Academy of Dermatology and Venereology
SubjectN4i 1: Pathogenesis and modulation of inflammation NCEBP 2: Evaluation of complex medical interventions
Corticosteroids are the mainstay of topical therapies for the treatment of mild to moderate psoriasis. Selection of vehicle, concentrations of corticosteroid and coadministered medications, and frequency of administration are critical factors that enhance bioavailability of topical corticosteroids. Topical corticosteroids are commonly used as polytherapy and combination therapy with other agents, such as salicylic acid, vitamin D analogues and tazarotene. Combinations are selected for the ability to enhance efficacy while minimizing corticosteroid-related side-effects, such as cutaneous atrophy. New, innovative products such as sprays, foams and nail lacquers provide opportunities to tailor treatment for individuals, which promotes patient adherence to medications. This review covers features of topical corticosteroid formulations that affect bioavailability, efficacy and safety when used as monotherapy and in combination with other agents for the treatment of mild to moderate psoriasis.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.